We caught up with Prof Thomas Lüscher (Royal Brompton and Harefield Hospital and Imperial College, London, UK) on the association between gut microbiota, the gut microbiome and cardiovascular disease.
- What is known about the association between gut microbiome changes and cardiovascular disease? (0.38)
- Which gut microbiota–dependent metabolites are involved in the pathogenesis of cardiovascular disease? (2.49)
- What novel therapeutic strategies are being investigated for targeting the gut microbiome to improve cardiovascular outcomes? (5.44)
- Could you give us an overview about the most important recent studies? (9.44)
- What are the major gaps in our knowledge and what future studies are planned? (12.13)
Speaker disclosures: Professor Thomas Lüscher has nothing to declare in relation to this video interview.
Support: Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Professor Thomas Lüscher, September 2020.
Share this Video
Related Videos In Cardiovascular Disease
Michael Reardon, ACC 2022: Insights From the Corevalve US Pivotal and SURTAVI Trials: Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses
Both the CoreValve US pivotal and SURTAVI trials investigated the five-year incidence, timing and predictors of haemodynamic valve deterioration of transcatheter aortic valve replacement (TAVR) surgery and surgical aortic bioprostheses in the treatment of severe, symptomatic aortic stenosis. Prof. Michael Reardon (Houston Methodist Hospital, Houston, TX) shares the insights and findings from these trials. Questions: […]
Milind Desai, ACC 2022: VALOR-HCM Trial
The VALOR-HCM trial showed the benefits of mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive hypertrophic cardiomyopathy. It was a pleasure to speak with Prof. Milind Desai (Cleveland Clinic, Cleveland, OH) about the VALOR-HCM trial including the efficacy and safety endpoints of it and what future […]
Milind Desai, ACC 2022: VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy
An overview about the risks of surgical septal myectomy and alcohol ablation as treatments for obstructive hypertrophic cardiomyopathy and how mavacamten can provide an alternative was given by Prof. Milind Desai (Cleveland Clinic, Cleveland, OH). The presentation entitled ‘VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!